JPHRPHA@EC2702A

Citi Gives Hengrui Medicine H Shares 'Buy' Rating with Target Price

UBS Adjusts Hengrui Medicine's Profit Forecast and Maintains Buy Rating

HENGRUI PHARMA released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue HKD 9.229 B (forecast HKD 9.384 B), actual EPS HKD 0 (forecast HKD 0.3986)

Hengrui Medicine reports 21.78% increase in first quarter net profit

Hengrui Medicine's Subsidiary's SHR-A1811 Inclusion in Breakthrough Therapy List

Hengrui Medicine Subsidiary Obtains Clinical Trial Approval for HRS9531 Injection

Hengrui Medicine's Subsidiary's Drug SHR-A2102 Included in Breakthrough Therapy List

Hengrui Medicine's subsidiary receives clinical trial approval for new heart failure drug HRS-7156

HENGRUI PHARMA to Release FY2026 Q1 Earnings on April 22 After-Market (BJT), Forecast Revenue HKD 9.977 B, EPS HKD 0.3984

Hengrui Medicine repurchased 44,000 A-shares at a cost of 2.4513 million yuan

Morgan Stanley Increases Long Position in H Shares of Jiangsu Hengrui Medicine

Hengrui Medicine Implements Share Repurchase Plan

Morgan Stanley Upgrades Hengrui Medicine Rating, Predicts High Growth in Innovative Drug Sales

Jiangsu Hengrui's Subsidiary Approved to Start Clinical Trials for HRS9531

Hengrui Medicine Announces Yearly Performance, Revenue and Profit Both Increase

Hengrui Medicine Reports Revenue and Net Profit Growth in 2025 and Announces Dividend Plan

HENGRUI PHARMA released FY2025 Annual Earnings on March 25 After-Market (BJT), actual revenue HKD 34.57 B (forecast HKD 36.37 B), actual EPS HKD 1.2896 (forecast HKD 1.5097)

HENGRUI PHARMA released FY2025 Q4 earnings on March 25 After-Market (BJT), actual revenue HKD 9.387 B (forecast HKD 10.41 B), actual EPS HKD 0.3227 (forecast HKD 0.5764)

Suzhou Sunyanda Biopharmaceutical's SHR-A1811 Approved for Breast Cancer Treatment

Hengrui Medicine's SHR-3836 Injection Receives Clinical Trial Approval from NMPA

QINGDAO HLDGS

QIANHAI HEALTH

GUOXIA TECH

BITSTRAT HLDGS

KIN SHING HLDGS

AV CONCEPT HOLD

DATRONIX HOLD

HAITIAN ANTENNA

PRODUCTIVE TECH

INVESTECH HLDGS

KLRA

01276

600276

Kailera Therapeutics, a spin-off of Hengrui Pharma focused on weight-loss drugs, had a successful IPO on Nasdaq, validating the NewCo business model. Hengrui's stake in Kailera is valued at approximately $300 million after the stock surged 63% on its debut. This follows a trend of successful spin-offs in the Chinese pharmaceutical sector, enhancing investor confidence. The IPO raised $625 million, which will be used to advance Kailera's drug pipelines, positioning it against major competitors like Eli Lilly and Novo Nordisk. Morgan Stanley maintains an "overweight" rating on Hengrui, citing potential revenue growth from its GLP-1 portfolio.

benzinga_article

Kailera Therapeutics

Eli Lilly

HENGRUI PHARMA

Hengrui Pharma

KEYMED BIO-B

Gilead Sciences

Bain Capital Specialty Finance

Wave Life Sciences

Endra Life Sciences

Nano Labs

Atlas Growth Acquisition Ltd

Gallant Venture

Northern Venture Trust PLC

Western Asset High Inc II-RT

TWELVE SEAS INVESTMENT COMPANY III ORD USD0.0001 CL A (SUB/RTS)21/11/2030

Russell Investment Management LLC

Lyra Therapeutics

ORA Capital Partners Limited

Tyra Biosciences

Harvard Bioscience

Mustang Bio

Sonnet BioTherapeutic CVR

Forian

Forte Biosciences

FORTIOR

Oramed Pharma

OncoMed Pharmaceuticals, Inc.

ORIC Pharmaceuticals

Novo Nordisk AS

Morgan Stanley

ENDRA LIFE SCIENCES INC

FORTE BIOSCIENCES INC

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy

520690

UBS has raised the target price for Jiangsu Hengrui Pharmaceuticalsto HKD97.4 from HKD91, maintaining a Buy rating. The company reported a 1Q revenue of RMB8.14 billion, a 13% YoY increase, but slightly below market expectations. Net profit rose 21.8% YoY to RMB2.28 billion, aligning with forecasts. UBS adjusted its EPS forecasts downwards for 2026-2028 due to lower expectations for generic drug sales, but increased long-term sales forecasts due to R&D progress.

AASTOCKS News

Bosera Hang Seng SCHK Innovative Drug Select ETF

UBS Raises Jiangsu Hengrui Pharmaceuticals  TP to HKD97.4, Maintains Buy

516820

HENGRUI PHARMA's Q1 report shows revenue of 8.141 billion yuan, up 12.98% year-over-year; net profit attributable to parent company shareholders reached 2.282 billion yuan, a 21.78% increase. The share of innovative drug sales revenue exceeded 60% for the first time, reaching 61.69%, with non-oncology product revenue surging 92.13% year-over-year, highlighting a clear diversification trend. During the reporting period, cumulative R&D investment stood at 2.224 billion yuan, with 3 innovative achievements approved and 8 new drug marketing applications accepted, accelerating the pipeline progression

- On April 22, 2026, Heng Rui Medicine released its Q1 report, showing a revenue of 81.41 billion yuan, a 12.98% year-on-year increase.  
- The innovative drug business emerged as the core growth engine, with sales reaching 45.26 billion yuan, representing 61.69% of total revenues, and the company aims for over 30% growth in annual innovative drug sales.  
- Despite a decline in generic drug revenues due to strategic adjustments, the robust growth in non-tumor products reflects the successful diversification of the company's innovative pipeline.

Wallstreetcn

Ping An CSI Medicine and Medical Device Innovation ETF

GlaxoSmithKline plc

GSK plc Sponsored ADR

Innovative Drug Revenue Share Surpasses 60% for First Time, HENGRUI PHARMA Q1 Revenue Hits 8.14 Billion Yuan, Net Profit Up 22% | Earnings Report

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth | KLRA Stock News

StockTitan

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth | KLRA Stock News

Hengrui Pharma announced that its subsidiary Fujian Shengdi's HRS9531 injection has been approved by the National Medical Products Administration. This product will conduct clinical trials in overweight and obese adolescents. The marketing application for HRS9531 for long-term weight management in adults was accepted by the National Medical Products Administration in September 2025

AASTOCKS

Hengrui Pharma's subsidiary HRS9531 injection has been approved to conduct clinical trials

513060

Hengrui Pharma announced that the profit distribution plan for 2025 has been approved by shareholders at the shareholders' meeting, and a cash dividend of RMB 2 per 10 shares (including tax) will be distributed to all shareholders; the 2025 year-end dividend will be denominated in RMB and announced, and will be paid in RMB to the company's A-share shareholders, as well as a cash dividend of HKD 2.2828 per 10 shares to H-share shareholders. The 2025 year-end dividend is expected to be distributed to H-share shareholders on May 27, 2026

Bosera Hang Seng Health Care ETF(QDII)

Hengrui Pharma distributes a final dividend of 0.20 RMB per share to shareholders

Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that all resolutions at its 2025 AGM were approved, including cash dividends and board changes. Key decisions involved director appointments, retirement of an independent director, and changes in board committee composition. Notably, certain treasury shares had no voting rights, and related parties abstained from voting on specific resolutions. The company aims to enhance corporate governance transparency. Analysts rate the stock as a Buy with a target price of HK$92.00, reflecting confidence in its market position and growth potential.

Tip Ranks

Hengrui Pharma Shareholders Approve Dividends, Board Changes at 2025 AGM

03317

09866

03808

06809

01211

06618

01138

06181

00100

XUNCE(03317) rose 15.61%, with a trading turnover 2.7 Billion HKD, and a year-to-date rose 609.7%. NIO-SW(09866) rose 7.47%, with a trading turnover 339.3 Million HKD, and a year-to-date rose 27.9%. JD HEALTH(06618) fell 9.43%, with a trading turnover 695.0 Million HKD, and a year-to-date fell 16.3%. COSCO SHIP ENGY(01138) fell 4.45%, with a trading turnover 571.4 Million HKD, and a year-to-date rose 94.5%.

- The Hang Seng Index decreased by 0.9%, with a year-to-date increase of 0.1%.  
- The Hang Seng Technology Index fell by 0.79%, down 12.6% year-to-date, while Xunji (03317) surged by 15.61% with a trading volume of 2.66 billion HKD, totaling a 609.7% increase this year.  
- NIO-SW (09866) rose by 7.47%, with a trading volume of 340 million HKD, and JD Health (06618) dropped by 9.43%, totaling a 16.3% decrease year-to-date.

Top Gainers & Losers

XUNCE

NIO-SW

SINOTRUK

MONTAGE TECH

BYD COMPANY

JD HEALTH

COSCO SHIP ENGY

LAOPU GOLD

MINIMAX-W

Top 5 HK Stock Gainers/Losers (>100B) (4.13)

688428

02196

01858

688236

600196

09969

Over half of listed Chinese drugmakers reported increased net profits for 2025, driven by innovative medicines and overseas business. Notable performers include Hengrui Pharmaceuticals, with a 22% profit rise to CNY7.7 billion, and InnoCare Pharma, achieving its first profit of CNY642 million. Fosun Pharmaceutical Group's net profit rose 22% to CNY3.4 billion, while Chunlizhengda Medical Instruments saw a 118% profit surge. The industry is focusing on innovative R&D and adapting to evolving consumer demands, with firms emphasizing integration of online and offline services.

Yicai

InnoCare Pharma

FOSUN PHARMA

CHUNLI MEDICAL

Chunli Medical

INNOCARE

Over Half of Listed Chinese Drugmakers See 2025 Profit Grow Buoyed by Innovative Medicines, Overseas Business

159849

588130

516500

517110

510660

589720

159837

The 12th Annual China Healthcare Investment Conference (CHIC 2026) celebrated outstanding achievements in healthcare investment at its Awards Gala Dinner in Shanghai. The event recognized key players in the sector, awarding Insilico Medicine for IPO of the Year, and Kailera Therapeutics and Vor Bio for Private Financing of the Year. Hengrui Pharma-GSK and Innovent-Takeda shared the Deal of the Year award. The conference connects innovation and investment in China's healthcare, featuring leaders from venture capital, private equity, and the pharmaceutical industry.

prnewswire

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI Biotechnology Theme ETF

20:00 ETCHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala

The US imposed a 39% tariff on imported gold bars, sparking a rally in gold stocks, with Lao Feng Xiang rising nearly 4% again. The semiconductor sector was dragged down by SMIC's Q2 net profit plunging 19%, with most stocks falling.

SMIC

SMIC HK SDR 5to1

ZIJIN MINING

Zijin Mining

SD GOLD

SD-GOLD

Asymchem

ZHAOJIN MINING

HORIZONROBOT-W

LINGBAO GOLD

INNOSCIENCE

CE HUADA TECH

BATELAB

ZAI LAB

Zai Lab

TIGERMED

Tigermed

FRONTAGE

CHIFENG GOLD

TONGGUAN GOLD

CHI SILVER GP

HUA HONG SEMI

Hua Hong

Hot Trades in Hong Kong Stocks (8.8)｜Gold Sector Rises Across the Board on Tariff Catalysts, SMIC Leads Decline by 6%

Hong Kong stocks continued their upward trend on July 28, with the cryptocurrency, innovative drug, gaming, and insurance sectors performing well. Hong Kong's &#34;Stablecoin Ordinance&#34; will officially take effect on August 1, marking the countdown to stablecoin issuance; the innovative drug sector was boosted by Hengrui Pharmaceuticals securing a $12 billion order; insurance stocks extended their gains as industry anti-internal competition and interest rate cuts improved profit prospects; gaming stocks benefited from Macau's July gaming revenue exceeding expectations and Thailand's withdrawal of the casino bill.

INNOVENT BIO

3SBIO

CSPC PHARMA

OSL GROUP

CPIC

SUNSHINE INS

SANDS CHINA LTD

Sands China

WYNN MACAU

CR HOLDINGS

CHINA LIFE

China Life

SBP GROUP

MELCO INT'L DEV

GUOTAI JUNAN I

AIA-R

AIA Group

SJM HOLDINGS

Hot Trades in Hong Kong Stocks (7.28)｜Cryptocurrency, Innovative Drugs, Insurance, and Gaming Sectors Shine, Hengrui Pharmaceuticals Soars 15% at Midday

JPHRPHA@EC2702A(28519.HK)

JPHRPHA@EC2702A Stock Performance Chart

Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy

UBS Raises Jiangsu Hengrui Pharmaceuticals TP to HKD97.4, Maintains Buy

Innovative Drug Revenue Share Surpasses 60% for First Time, HENGRUI PHARMA Q1 Revenue Hits 8.14 Billion Yuan, Net Profit Up 22% | Earnings Report

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth | KLRA Stock News

Hengrui Pharma's subsidiary HRS9531 injection has been approved to conduct clinical trials